Skip to content
Screener

Ardelyx ARDX Product supply revenue — Total revenues

Other product segments

IBSRELA
$86.24M+32.6%
XPHOZAH
$31.89M+27.4%
Non-cash royalty revenue related to the sale of future royalties
$676K-51.0%
Licensing revenue
$96K+380%

Similar metrics at other companies

Kinetik Holdings logo
KNTKProduct revenue — Total revenues
$312.23M-0.1%
Quanterix Corporation logo
QTRXProduct revenue — Total revenues
$23.48M+39.5%
Cactus logo
WHDProduct revenue — Total revenues
$297.24M+42.2%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Geron logo
GERNGross product revenue — Total revenues
$72.44M+25.2%
Geron logo
GERNProduct revenue, net — Total revenues
$57.47M+17.3%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$1.2B-4.0%
Enterprise value$1.36B-0.6%
P/S2.7×-0.6×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues
Product sales, net$118,129$90,077$211,502$157,891
Product supply revenue1,9766,1852,3306,439
Licensing revenue96201475,040
Non-cash royalty revenue related to the sale of future royalties6761,3801,3712,406
Total revenues120,87797,662215,350171,776
Costs and operating expenses
Cost of sales5,75912,40310,57024,706

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's product supply revenue — total revenues?
Ardelyx (ARDX) reported product supply revenue — total revenues of $1.98M in Q2 2026.
How has Ardelyx's product supply revenue — total revenues changed year-over-year?
Ardelyx's product supply revenue — total revenues decreased by 68.1% year-over-year, from $6.19M to $1.98M.
What is the long-term trend for Ardelyx's product supply revenue — total revenues?
Over 4 years (2021 to 2025), Ardelyx's product supply revenue — total revenues has grown at a 103.7% compound annual growth rate (CAGR), from $922K to $15.88M.
What does product supply revenue — total revenues mean?
This metric represents the total revenue generated specifically from the sale and distribution of proprietary pharmaceutical products. It reflects the commercial success and market adoption of the company's therapeutic offerings within its target patient populations. Tracking this revenue stream is essential for evaluating the transition from clinical development to commercial-stage operations and assessing the scalability of the company's product portfolio.

Ask your AI about Ardelyx's product supply revenue — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude